EP
LUCD icon

Essential Partners’s Lucid Diagnostics LUCD Stock Holding History

Essential Partners’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$30 Sell
40
-527
-93% -$492 ﹤0.01% 2803
2026
Q2 		$607 Sell
567
-2,271
-80% -$2.45K ﹤0.01% 2431
2026
Q1 		$3.26K Buy
+2,838
New +$3.61K ﹤0.01% 1781
2025
Q4 		– Sell
-1
Closed -$1 – 2859
2025
Q3 		$1 Buy
+1
New +$1 ﹤0.01% 2668

Other funds holding LUCD

Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
TIA
Traphagen Investment Advisors Oradell, New Jersey $1.46B AUM 14.92% 1-Year Est. Return
Sax Wealth Advisors
Sax Wealth Advisors Parsippany, New Jersey $3.5B AUM 13.73% 1-Year Est. Return
AP
Anchyra Partners Atlanta, Georgia $477M AUM 34.33% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners's LUCD Position: Q3 2026 in Review

Essential Partners reduced its Lucid Diagnostics (LUCD) stake by 93% in Q3 2026, selling an estimated $492 and leaving 40 shares worth $30. The position accounts for ﹤0.01% of the portfolio, ranked #2803.

Essential Partners first reported a position in LUCD in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.26K in Q1 2026. 9 funds tracked by Wall St. Rank hold LUCD as of Q3 2026.

  • Essential Partners held 40 shares of Lucid Diagnostics worth $30 as of Q3 2026.
  • Essential Partners sold 527 Lucid Diagnostics shares in Q3 2026, an estimated $492.
  • Lucid Diagnostics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2803 holding.
  • Essential Partners first reported a position in Lucid Diagnostics in Q3 2025 and has held it in 4 quarters since.
  • Essential Partners's Lucid Diagnostics position peaked at $3.26K in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.